Table 1:
Unmatched comparison between patients with and without neoadjuvant treatment undergoing lobectomy
| Variables | Without neoadjuvant (42 568 patients) | With neoadjuvant (3827 patients) | Standardized difference (%) |
|---|---|---|---|
| Age (years), mean (SD) | 65.0 (9.4) | 61.6 (8.9) | 37 |
| Female gender, n (%) | 14 169 (33) | 1177 (31) | 5 |
| BMI (kg/m2), mean (SD) | 25.5 (4.1) | 25.1 (4.0) | 10 |
| ppoFEV1%, mean (SD) | 73.2 (17.1) | 71.2 (16.2) | 11 |
| CAD, n (%) | 3865 (9.1) | 299 (7.8) | 4 |
| CVD, n (%) | 1443 (3.4) | 95 (2.5) | 5 |
| Diabetes, n (%) | 1565 (3.6) | 119 (3.1) | 3 |
| PS >1, n (%) | 3009 (7.1) | 313 (8.2) | –4 |
| Minimally invasive access, n (%) | 10 042 (24) | 295 (7.7) | 38 |
| pT stage >1, n (%) | 26 717 (63) | 2515 (66) | 6 |
| pN stage positive, n (%) | 14 477 (34) | 1789 (47) | 27 |
BMI: body mass index; CAD: coronary artery disease; CVD: cerebrovascular disease; pN: pathological nodal stage; ppoFEV1: predicted postoperative forced expiratory volume in 1 s; PS: performance score; pT: pathological tumour stage; SD: standard deviation.